The frequency of adverse events ( linagliptin 81.3 % , placebo 91.9 % ) and hypoglycemia ( Week 24 : linagliptin 25.0 % , placebo 25.7 % ; treatment end : linagliptin 28.8 % , placebo 35.1 % ) was similar between groups .